172 related articles for article (PubMed ID: 38253746)
1. Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis.
Li MT; He Y; Huang SY; Hu X; Chen JS
Invest New Drugs; 2024 Feb; 42(1):116-126. PubMed ID: 38253746
[TBL] [Abstract][Full Text] [Related]
2. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
Monge C; Maeng H; Brofferio A; Apolo AB; Sathya B; Arai AE; Gulley JL; Bilusic M
J Immunother Cancer; 2018 Dec; 6(1):150. PubMed ID: 30563577
[TBL] [Abstract][Full Text] [Related]
3. Asymptomatic Myocarditis with Mild Cardiac Marker Elevation Following Nivolumab-Induced Myositis.
Shindo A; Yamasaki M; Uchino K; Yamasaki M
Int Heart J; 2022; 63(1):180-183. PubMed ID: 35095069
[TBL] [Abstract][Full Text] [Related]
4. Ipilimumab- and nivolumab-induced myocarditis in a patient with metastatic cholangiocarcinoma: a case report.
Delombaerde D; Vervloet D; Berwouts D; Beckers R; Prenen H; Peeters M; Gremonprez F; Croes L; Vulsteke C
J Med Case Rep; 2022 Jul; 16(1):275. PubMed ID: 35831829
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab-induced myocarditis complicated by complete atrioventricular block in a patient with metastatic non-small cell lung cancer.
Tan JL; Mugwagwa AN; Cieslik L; Joshi R
BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31300602
[TBL] [Abstract][Full Text] [Related]
6. Analysis of clinical characteristics of mesalazine-induced cardiotoxicity.
Chen J; Duan T; Fang W; Liu S; Wang C
Front Pharmacol; 2022; 13():970597. PubMed ID: 36188558
[No Abstract] [Full Text] [Related]
7. Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma.
Chen Q; Huang DS; Zhang LW; Li YQ; Wang HW; Liu HB
Clin Toxicol (Phila); 2018 Jul; 56(7):667-671. PubMed ID: 29126352
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab-induced Myocarditis Successfully Treated with Corticosteroid Therapy: A Case Report and Review of the Literature.
Matsuo K; Ishiguro T; Najama T; Shimizu Y; Kobayashi Y; Mutou M
Intern Med; 2019 Aug; 58(16):2367-2372. PubMed ID: 31118387
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
[TBL] [Abstract][Full Text] [Related]
10. Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab.
Yamaguchi S; Morimoto R; Okumura T; Yamashita Y; Haga T; Kuwayama T; Yokoi T; Hiraiwa H; Kondo T; Sugiura Y; Watanabe N; Kano N; Kohno K; Fukaya K; Sawamura A; Yokota K; Ishii H; Nakaguro M; Akiyama M; Murohara T
Can J Cardiol; 2018 Jun; 34(6):812.e1-812.e3. PubMed ID: 29801747
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
Suzuki S; Ishikawa N; Konoeda F; Seki N; Fukushima S; Takahashi K; Uhara H; Hasegawa Y; Inomata S; Otani Y; Yokota K; Hirose T; Tanaka R; Suzuki N; Matsui M
Neurology; 2017 Sep; 89(11):1127-1134. PubMed ID: 28821685
[TBL] [Abstract][Full Text] [Related]
12. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
[TBL] [Abstract][Full Text] [Related]
13. Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.
Sarocchi M; Grossi F; Arboscello E; Bellodi A; Genova C; Dal Bello MG; Rijavec E; Barletta G; Rossi G; Biello F; Ghigliotti G; Canepa M; Mussap M; Brunelli C; Spallarossa P
Oncologist; 2018 Aug; 23(8):936-942. PubMed ID: 29567824
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy.
Balanescu DV; Donisan T; Palaskas N; Lopez-Mattei J; Kim PY; Buja LM; McNamara DM; Kobashigawa JA; Durand JB; Iliescu CA
Cardiovasc Pathol; 2020; 47():107211. PubMed ID: 32268262
[TBL] [Abstract][Full Text] [Related]
15. A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies.
Guo CW; Alexander M; Dib Y; Lau PKH; Weppler AM; Au-Yeung G; Lee B; Khoo C; Mooney D; Joshi SB; Creati L; Sandhu S
Eur J Cancer; 2020 Jan; 124():15-24. PubMed ID: 31707280
[TBL] [Abstract][Full Text] [Related]
16. An Autopsy Case of Late-onset Fulminant Myocarditis Induced by Nivolumab in Gastric Cancer.
Naganuma K; Horita Y; Matsuo K; Miyama Y; Mihara Y; Yasuda M; Nakano S; Hamaguchi T
Intern Med; 2022 Oct; 61(19):2867-2871. PubMed ID: 35249925
[TBL] [Abstract][Full Text] [Related]
17. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
[TBL] [Abstract][Full Text] [Related]
18. Fatal myocarditis after the first dose of nivolumab.
Zomborska E; Kasperova S; Slopovsky J; Pazderová N; Kasperova B; Penz P; Nyitrayová O; Salek T; Porsok S; Mladosievicova B; Mego M
Klin Onkol; 2022; 35(6):486-492. PubMed ID: 36513516
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis.
Wang C; Zeng H; Fang W; Song L
Invest New Drugs; 2023 Apr; 41(2):333-339. PubMed ID: 36988830
[TBL] [Abstract][Full Text] [Related]
20. Smoldering myocarditis following immune checkpoint blockade.
Norwood TG; Westbrook BC; Johnson DB; Litovsky SH; Terry NL; McKee SB; Gertler AS; Moslehi JJ; Conry RM
J Immunother Cancer; 2017 Nov; 5(1):91. PubMed ID: 29157297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
